Home > Insights > Bioinformatics Holds the Promise of Developing Personalized Treatment for Cancer Patients

Bioinformatics Holds the Promise of Developing Personalized Treatment for Cancer Patients

In May 2016, Pacific Northwest Research Institute (PNRI) and Indivumed GmbH (Indivumed), based in Hamburg, Germany, entered a strategic collaboration led by PNRI’s David Galas, PhD. The collaboration is designed to harness the power of molecular and clinical cancer data for tailoring successful treatments for individual cancer patients.

Indivumed’s global Cancer Database and Biobank contains more than 4.5 million biological data points associated with greater than 600,000 discrete tumor, blood and urine samples obtained from more than 25,000 cancer patients. Indivumed stringently follows highly standardized processes for the collection and preservation of biospecimen samples from cancer patients, which results in the highest quality molecular and clinical datasets.

Working Together

“Accessing Indivumed’s global Cancer Database is a great opportunity for us to better understand how all the pieces of a cancer patient’s biology fit together by detecting complex dependencies in this extensive data set,” said David. “Understanding the biology of cancer from the patient data will provide invaluable insight into various cancers and how to treat it in the most precise manner.”

The Galas Lab will apply its proprietary computational method for deciphering the biological complexity of human development and disease. “The method has been successfully used to analyze a wide variety of data ranging from RNA profiles in patients with autoimmune disease to childhood development,” said Nikita Sakhanenko, PhD, Senior Staff Scientist in PNRI’s Galas Lab. “This collaboration will be the first application of the method in cancer.”

Hartmut Juhl, Founder and Chief Executive Officer of Indivumed, commented that “allowing David’s extremely innovative analytical platform to survey our Cancer Database will enable Indivumed and collaborative research partners to better understand the complexity of cancer and to translate their specific targets and biomarkers in the context of the clinical world of cancer. Overall, we hope to get closer to the development of a true precision medicine for cancer patients.”

About Indivumed GmbH

Indivumed GmbH, a physician-led, integrated global oncology company based in Hamburg, Germany, has established the world’s leading Cancer Database and biobank, retaining unique patterns of biomolecules such as RNA, DNA, and proteins as they existed in the human body. This Cancer Database makes possible multi-omics capabilities that will allow for characterization of samples and data such as whole genome gene expression analysis, expression analysis of cancer relevant proteins, expression analysis of cancer relevant phosphoproteins and bioinformatic solutions for integrating molecular, biological and clinical information.

Indivumed’s products and services allow for in-depth understanding of the underlying mechanisms of a patient’s cancer, addressing important demands in translational research and molecular diagnostics to support implementation of personalized healthcare.

PNRI is supported by

The SwedishSeattle MetSheratonTryskUSIK L GatesKinzer Partners

Support our innovative genetic research. Become a donor today.